THE 100 MOST INFLUENTIAL FIFTIERS OF THE WORLD — Global Ranking 2027 #001 | Peter H. Diamandis: the man turning longevity into one of the defining industries of the 21st century

Some people participate in industries. Others help create them. Peter H. Diamandis clearly belongs to the second category.

A Harvard-trained physician, MIT engineer, entrepreneur, investor and founder of XPRIZE, Diamandis has spent decades pursuing one central conviction: some of humanity’s greatest challenges can be accelerated toward solutions when science, capital, competition and exponential technologies converge around sufficiently ambitious goals.

At 65, his influence is particularly relevant to FIFTIERS because he represents something far larger than the anti-aging movement. Diamandis is helping move longevity from what was once a relatively peripheral scientific ambition into a global economic category, connecting artificial intelligence, preventive medicine, biotechnology, advanced diagnostics, investment, entrepreneurship and entirely new expectations of what it might mean to be 60, 70, 80 or even 100 years old. Born in 1961, he has founded or co-founded more than 25 companies spanning health, technology, space, education and venture capital.

His contribution to the emerging longevity ecosystem can be seen across several fronts at once. He is a co-founder of Fountain Life, a company built around a fundamental transformation of medicine: moving away from reacting to disease after symptoms emerge and toward identifying risks earlier through precision diagnostics, extensive health data, artificial intelligence and personalized medicine. Fountain Life positions itself around early detection, prevention and healthspan optimization, with Diamandis continuing to serve as a co-founder and executive chairman.

Yet his potentially most powerful contribution may be XPRIZE Healthspan, the $101 million global competition designed to accelerate therapies capable of restoring age-related muscle, cognitive and immune function in adults between 50 and 90. The objective is not simply to keep people alive longer. It is to restore additional years of functional capacity. In August 2026, the competition announced another major stage as finalist teams advanced toward clinical testing, demonstrating how longevity research is increasingly moving from theory toward real-world intervention.

That conceptual shift matters enormously. For most of the twentieth century, aging was primarily treated as a demographic reality. The new generation of longevity-science companies is beginning to treat it as a technological problem that may increasingly become open to intervention.

And once a problem can be measured, financed, researched and potentially modified, an industry begins to form around it.

Diamandis understood this transition earlier than many traditional corporate leaders.

His investment activity further expands that influence. Through vehicles including BOLD Capital Partners, he has helped connect venture capital with exponential technologies and companies operating across longevity, biotechnology and healthtech. His combination of entrepreneurial, educational and investment platforms gives him an unusual position: he can simultaneously generate ideas, finance businesses, popularize technologies and help create markets. XPRIZE reports that competitions launched under his leadership have mobilized hundreds of millions of dollars in prize capital while stimulating billions of dollars in broader research and development activity.

He has also helped reshape the cultural narrative surrounding age. His thesis is not simply about adding years to life. It is about remaining sufficiently healthy long enough to benefit from successive generations of medical innovation. AI-powered diagnostics, genomic sequencing, cellular therapies, regenerative medicine, continuous sensors, new biomarkers and cellular reprogramming increasingly become components of the same technological architecture.

In 2026, Diamandis argued that radically extending human healthspan could represent an economic opportunity of extraordinary scale. Behind the headline lies a question that governments, insurers, investors and multinational corporations are only beginning to confront: what happens to the global economy if tens of millions of people remain healthy, productive and economically active for an additional ten, twenty or thirty years?

Almost every industry would change.

Pension systems would change. Labor markets would change. Insurance would change. Housing would change. Wealth management would change. Premium consumption would change. Education would change. Intergenerational relationships would change. Entirely new industries would emerge to serve a population possessing more years, more accumulated knowledge and, in many cases, greater financial capacity.

That is precisely why Peter Diamandis belongs in the conversation surrounding THE 100 MOST INFLUENTIAL FIFTIERS OF THE WORLD — Global Ranking 2027.

Not simply because he has become one of longevity’s most recognizable international advocates. Nor merely because he has built companies and financed technologies associated with longer, healthier lives.

His deeper influence comes from recognizing that extending healthy human life is not merely a medical challenge.

It is an economic transformation.

And potentially one of the defining transformations of the twenty-first century.

FIFTIERS EDITORIAL VERDICT: Peter H. Diamandis deserves consideration among the leading candidates for the Global Ranking 2027 because he embodies the convergence of longevity, capital, innovation and entrepreneurial vision. At 65, he continues to build companies, finance emerging technologies and articulate a new interpretation of aging in which additional years of life are no longer viewed primarily as a societal burden, but increasingly as a new frontier for wealth creation, knowledge and human progress.

THE 100 MOST INFLUENTIAL FIFTIERS OF THE WORLD™
Global Ranking 2027 — A FIFTIERS Magazine editorial series.